Compugen
Israeli biopharmaceutical company specializing in computational discovery and development of cancer immunotherapy drugs. Listed on NASDAQ and Tel Aviv Stock Exchange.
Compugen is an Israeli biopharmaceutical company that combines computational biology, immunoinformatics, and drug discovery to develop novel cancer immunotherapy candidates. Founded in 1993, Compugen pioneered computational approaches to target discovery and has evolved into a clinical-stage biotech company.
Technology Platform
Compugen's proprietary computational discovery platform analyzes genomic and proteomic data to identify novel immunotherapy targets. The platform leverages machine learning, bioinformatics, and immunology to predict therapeutic candidates. This "reverse immunology" approach has generated a pipeline of monoclonal antibodies and checkpoint inhibitors targeting immune checkpoint and immunosuppressive pathways in cancer.
Pipeline & Clinical Development
Compugen's lead program is COM701 (anti-PVRL2 antibody for cancer immunotherapy), in clinical trials. Other programs target immune checkpoints and tumor microenvironment modulation. The company is advancing candidates in solid tumors (lung, colorectal, ovarian) and hematologic malignancies.
Capital Structure & Funding
Compugen has raised venture capital from Israeli and international investors (aMoon Fund, Kfir Ventures, others) and conducted secondary offerings on NASDAQ. As a clinical-stage biotech, the company burns cash and relies on capital markets access. Burn rate and pipeline progress are key valuation drivers.
Business Model & Partnerships
Compugen develops drugs internally and is also exploring partnerships with larger pharma (development/commercialization) and out-licensing its computational platform to pharma giants seeking target discovery services. Strategic collaborations offset R&D costs and reduce development risk.
Regulatory & Clinical Risk
As an immunotherapy company in oncology, Compugen faces high clinical risk (trial failure rates ~90% in immuno-oncology). Regulatory approval timelines are uncertain; safety and efficacy readouts are closely watched by investors. A successful approval could transform the company into a commercial-stage biotech.
Israeli Biotech Positioning
Compugen represents Israel's computational biotech strength—combining theoretical research, algorithmic innovation, and pharma-grade drug development. The company attracts Israeli and diaspora talent and competes with global biotech centers (Boston, San Francisco, Cambridge) on innovation velocity.